All the organizing institutions have decided to discuss current developments on the translation of outcomes of large-scale molecular analyses into novel diagnostic tools and targeted therapies.
Accordingly, they have delegated their leading senior scientists to take part in this important debate. The list of over 30 confirmed invited speakers is extraordinary, and includes word leaders in oncology and bioinformatics, and the cream of Polish cancer researchers and medical oncologists.
Moreover, the floor is open for all interested researchers in the field, especially for young scientists, including students and postgraduates.
Please submit abstracts of your work for presentations. The topics to be specifically discussed, albeit not exclusively, are: i Cancer biology, epigenetics and cancer stem cells; ii Heterogeneity of cancer and therapeutic implications; iii Clinical trials of targeted therapeutics; iv Cancer immunotherapy; v The Cancer Genome Atlas Project and targeting cancer subsets; vi Cancer bioinformatics and Big Data analyses; vii Nanotechnologies for cancer diagnostics and therapies; viii Multidisciplinary treatment of selected tumor types.
We trust that Contemporary Oncology and cancer patients will significantly benefit from the Conference. We expect to publish as much as possible from the topics discussed to form a platform for further collaboration, exchange of ideas, technology and expertise.
In addition, we trust that the publication will be cited by others. The translation of cancer genomics into targeted therapies and diagnostic biomarkers by means of data analysis has launched a new era of personalized oncology.
On the other hand, the field of cancer immunology has again become an exciting place where basic science is having tremendous translational impact and cancer immunotherapy is on the brink of becoming mainstream clinical practice. The concepts of cancer stem cells, cancer epigenetics and metabolism have deeply expanded our understanding of how cancer cells interact with their niche and microenvironment. In recognition, the Polish Oncology Consortium, the University of Texas MD Anderson Cancer Center in Houston, and Institute Gustave-Roussy in Paris are pleased to announce a symposium focused on the exciting field of cancer genomics, personalized oncology, and immunotherapy.
Vicktoria Shuffelton, DO, Family Medicine Specialist
We will bring together academic and industry researchers, and clinical oncologists to explore how genomics and big data analysis is impacting the development of modern diagnostics and targeted cancer treatments.
We aim to foster discussion on recent findings in cancer genomics, epigenetics, cancer stem cells, and new approaches in cancer immunotherapy.
About the conference The translation of cancer genomics into targeted therapies and diagnostic biomarkers by means of data analysis has launched a new era of personalized oncology.